ArticleActa ophthalmologica2025
Preservatives in artificial tears: Assessing impact on dry eye symptoms: Findings from 67 951 questionnaire responses-Project FOREVER.
Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Switching from preserved to preservative-free artificial tears and short-term change in dry eye symptoms and signs: a prospective self-controlled clinic cohort.International ophthalmology · 2026Observational
- Marine-Derived Neoagarotetraose Alleviates Dry Eye Disease by Suppressing Inflammation and Apoptosis in a Murine Model.Marine drugs · 2026Article
- Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy.Frontiers in pharmacology · 2026Article
- Efficacy and Safety of 0.3% Preservative-Free Hyaluronic Acid-Based Eye Drops for the Management of Moderate to Severe Dry Eye Disease: A Prospective, Multicenter, Clinical Investigation.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling.Frontiers in medicine · 2026Article
- Preservatives in artificial tears: Assessing impact on dry eye symptoms: Findings from 67 951 questionnaire responses-Project FOREVER.Acta ophthalmologica · 2025Article
- Comparative Efficacy of Platelet-Rich Plasma, Autologous Serum, and Artificial Tears in Dry Eye Disease: A Systematic Review and Meta-Analysis.Biomedicines · 2025Review
- Stability of BTI Devices for Plasma Rich in Growth Factors (PRGF) Eye Drop Delivery Under Varying Storage and Handling Conditions.Biomedicines · 2025Article
- Evaluation of the usability, efficacy and safety of a novel ophthalmic eye drop dispenser designed to deliver preservative-free artificial tears for the treatment of dry eye disease.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo examine the association between the presence of dry eye disease (DED) symptoms when using BAK-preserved artificial tears (AT) compared to preservative-free AT.
methodsIn this cross-sectional study, we used data collected as part of Project 'Finding Ophthalmic Risk and Evaluating the Value of Eye exams and their predictive Reliability' (FOREVER). To analyse the strength and direction of associations, we used binomial logistic regression models adjusted for age, sex, smoking and eye diseases. The analysis was conducted on responses regarding AT formulations and seven distinct DED symptoms from 67 951 participants in Project FOREVER, including 8039 AT users.
resultsOur analysis showed statistically significant higher odds ratios (ORs) of experiencing itching and blurred vision among users of BAK-preserved AT compared to preservative-free AT users, with ORs of 1.26 (95% CI 1.01-1.58) and 1.28 (95% CI 1.02-1.60), respectively. Additionally, a borderline significant trend indicated an increased number of DED symptoms in the BAK-preserved AT group compared to preservative-free AT users. Furthermore, our study provided a comprehensive overview of AT usage patterns within the cohort, illustrating the proportion of users for each type of AT.
conclusionOur findings suggest that BAK-preserved AT may worsen DED symptoms. We found higher ORs for experiencing itching and blurred vision as well as a tendency towards experiencing a higher number of symptoms when using BAK-preserved AT compared to preservative-free AT. Further longitudinal studies with additional questions on AT usage and clinical assessments are needed to validate these findings and optimize AT formulations for safer, effective DED management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.